BR112013010774A2 - "usos de crofelemer no tratamento de diarreia associada ao hiv" - Google Patents

"usos de crofelemer no tratamento de diarreia associada ao hiv"

Info

Publication number
BR112013010774A2
BR112013010774A2 BR112013010774A BR112013010774A BR112013010774A2 BR 112013010774 A2 BR112013010774 A2 BR 112013010774A2 BR 112013010774 A BR112013010774 A BR 112013010774A BR 112013010774 A BR112013010774 A BR 112013010774A BR 112013010774 A2 BR112013010774 A2 BR 112013010774A2
Authority
BR
Brazil
Prior art keywords
crofelemer
hiv
treatment
associated diarrhea
diarrhea
Prior art date
Application number
BR112013010774A
Other languages
English (en)
Portuguese (pt)
Inventor
Bortey Enoch
Chaturvedi Pravin
King Steven
Original Assignee
Napo Pharmaceuticals Inc
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45994461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013010774(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Napo Pharmaceuticals Inc, Salix Pharmaceuticals Ltd filed Critical Napo Pharmaceuticals Inc
Publication of BR112013010774A2 publication Critical patent/BR112013010774A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
BR112013010774A 2010-10-31 2011-10-31 "usos de crofelemer no tratamento de diarreia associada ao hiv" BR112013010774A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40862210P 2010-10-31 2010-10-31
US40933510P 2010-11-02 2010-11-02
US41624910P 2010-11-22 2010-11-22
US201161434379P 2011-01-19 2011-01-19
PCT/US2011/058549 WO2012058664A1 (en) 2010-10-31 2011-10-31 Methods and compositions for treating hiv-associated diarrhea

Publications (1)

Publication Number Publication Date
BR112013010774A2 true BR112013010774A2 (pt) 2017-03-21

Family

ID=45994461

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013010774A BR112013010774A2 (pt) 2010-10-31 2011-10-31 "usos de crofelemer no tratamento de diarreia associada ao hiv"

Country Status (20)

Country Link
US (4) US8962680B2 (enExample)
EP (1) EP2632550B1 (enExample)
JP (2) JP6063385B2 (enExample)
CN (2) CN103370101A (enExample)
AU (1) AU2011320155B2 (enExample)
BR (1) BR112013010774A2 (enExample)
CA (1) CA2816416C (enExample)
DK (1) DK2632550T3 (enExample)
EC (1) ECSP13012650A (enExample)
ES (1) ES2635435T3 (enExample)
HK (1) HK1249036A1 (enExample)
HU (1) HUE035393T2 (enExample)
MX (1) MX348184B (enExample)
PE (1) PE20140036A1 (enExample)
PH (1) PH12013500857A1 (enExample)
PL (1) PL2632550T3 (enExample)
PT (1) PT2632550T (enExample)
RU (1) RU2597746C2 (enExample)
WO (1) WO2012058664A1 (enExample)
ZA (1) ZA201303136B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616012T3 (es) * 2006-05-01 2017-06-09 Napo Pharmaceuticals, Inc. Composiciones para tratar o prevenir enfermedad inflamatoria del intestino
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
NZ572049A (en) 2006-05-01 2012-08-31 Napo Pharmaceuticals Inc Method for treatment of constipation-predominant irritable bowel syndrome
PT2632550T (pt) 2010-10-31 2017-08-02 Napo Pharmaceuticals Inc Métodos e composições para tratar diarreia associada a vih
JP2016505561A (ja) * 2012-12-07 2016-02-25 サリックス ファーマスーティカルズ，リミテッド Ｈｉｖ関連下痢を治療する方法および組成物
US11389424B2 (en) 2017-03-09 2022-07-19 Napo Pharmaceuticals, Inc. Methods and compositions for treating chemotherapy-induced diarrhea
JOP20190276A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة
JOP20190275A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج اضطراب إسهال خِلقي
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
BR112022025741A2 (pt) * 2020-06-19 2023-01-03 Napo Pharmaceuticals Inc Usos de composições compreendendo crofelemer para tratamento de diarreia induzida por quimioterapia (cid)
WO2022115481A1 (en) * 2020-11-24 2022-06-02 Napo Pharmaceuticals, Inc. Methods and compositions for treating post-acute infection gastrointestinal disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
ATE430477T1 (de) 1996-10-16 2009-05-15 Napo Pharmaceuticals Inc Enteral-formulierungen von proanthocyanidzusammensetzungen gegen diarrhöe
WO2000047062A2 (en) 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
US20040071793A1 (en) 2002-10-05 2004-04-15 Bobrowski Paul J. Oral rehydration methods and compositions
US20080025966A1 (en) * 2004-01-30 2008-01-31 Currie Mark G Methods And Compositions For The Treatment Of Gastrointestinal disorders
EP1937655A1 (en) * 2005-06-22 2008-07-02 University of Massachusetts Hiv-1 protease inhibitors, and methods of making and using them
WO2007068383A1 (en) 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl ureas for treating virus infections
ES2616012T3 (es) 2006-05-01 2017-06-09 Napo Pharmaceuticals, Inc. Composiciones para tratar o prevenir enfermedad inflamatoria del intestino
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
NZ572049A (en) * 2006-05-01 2012-08-31 Napo Pharmaceuticals Inc Method for treatment of constipation-predominant irritable bowel syndrome
US20100092479A1 (en) 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
EA023814B1 (ru) 2009-08-26 2016-07-29 Гленмарк Фармасьютикалс Лтд. Способ получения полимерных композиций на основе проантоцианидина для фармацевтических форм
JP2013506716A (ja) * 2009-10-06 2013-02-28 ザ レゲンツ オブ ジ ユニヴァーシティ オブ カリフォルニア クロフェレマーなどのプロアントシアニジンオリゴマーを用いて疾患を治療する方法
US20110087530A1 (en) 2009-10-09 2011-04-14 Visa U.S.A. Inc. Systems and Methods to Provide Loyalty Programs
PT2632550T (pt) 2010-10-31 2017-08-02 Napo Pharmaceuticals Inc Métodos e composições para tratar diarreia associada a vih
RU2593014C2 (ru) 2011-01-27 2016-07-27 Гленмарк Фармасьютикалс Лимитед Способ производства проантоцианидиновой полимерной композиции
MY197454A (en) 2011-12-22 2023-06-19 Napo Pharmaceuticals Inc Non-enteric pharmaceutical composition comprising crofelemer
JP2016505561A (ja) 2012-12-07 2016-02-25 サリックス ファーマスーティカルズ，リミテッド Ｈｉｖ関連下痢を治療する方法および組成物

Also Published As

Publication number Publication date
RU2013123794A (ru) 2014-12-10
US20120184605A1 (en) 2012-07-19
CA2816416A1 (en) 2012-05-03
ECSP13012650A (es) 2013-10-31
HK1249036A1 (zh) 2018-10-26
JP6310971B2 (ja) 2018-04-11
AU2011320155B2 (en) 2016-02-25
PH12013500857A1 (en) 2018-01-17
US20120107370A1 (en) 2012-05-03
JP2013540826A (ja) 2013-11-07
MX348184B (es) 2017-06-02
US20150190367A1 (en) 2015-07-09
US9585868B2 (en) 2017-03-07
RU2597746C2 (ru) 2016-09-20
EP2632550A1 (en) 2013-09-04
ES2635435T3 (es) 2017-10-03
PT2632550T (pt) 2017-08-02
CA2816416C (en) 2020-02-11
AU2011320155A1 (en) 2013-05-09
CN103370101A (zh) 2013-10-23
US8962680B2 (en) 2015-02-24
PL2632550T3 (pl) 2017-10-31
JP6063385B2 (ja) 2017-01-18
WO2012058664A1 (en) 2012-05-03
HUE035393T2 (en) 2018-05-02
DK2632550T3 (en) 2017-08-07
EP2632550B1 (en) 2017-05-03
CN107595836A (zh) 2018-01-19
ZA201303136B (en) 2016-01-27
JP2017019806A (ja) 2017-01-26
PE20140036A1 (es) 2014-01-31
US20140294903A1 (en) 2014-10-02
EP2632550A4 (en) 2014-04-23
MX2013004873A (es) 2013-08-21

Similar Documents

Publication Publication Date Title
BR112013010774A2 (pt) "usos de crofelemer no tratamento de diarreia associada ao hiv"
HUS2400017I1 (hu) Dolutegravir és lamivudin kombinációi HIV-fertõzés kezelésére
IL308158A (en) Rna-guided human genome engineering
IL253225A0 (en) Sulfamoyl-arylamides and their use as drugs to treat jaundice b
GB2478595B (en) Phytocannabinoids in the treatment of glioma
CL2014002631A1 (es) Anticuerpos anti - hla - b*27 y usos de estos
SI2935303T1 (sl) 4'-fluoro-nukleozidi, 4'-fluoro-nukleotidi in njihovi analogi za zdravljenje HCV
IT1402907B1 (it) Composizioni topiche per mantenere o ripristinare l'integrita' delle mucose.
PL2448734T3 (pl) Preforma, pojemnik i sposób formowania pojemnika
EP2934378A4 (en) CATHETER ORIENTATION MARKER
BR112014030953A2 (pt) "dispositivo de diagnóstico in vitro e usos"
EP2878627A4 (en) THERMOPLASTIC RESIN COMPOSITION AND FILM THEREWITH
EP2640257A4 (en) EFFECTIVE SHIELDING AND REFRACTION TARGETS
EP2650328A4 (en) MODIFIED POLYPROPYLENE COMPOSITION AND LAMINATE THEREWITH
EP2855363A4 (en) WATER TREATMENT
BR112013007039A2 (pt) "composição de tratamento pessoal"
LT2531124T (lt) Prietaisai odos pažeidimams gydyti
ZA201202797B (en) The use of a herbal composition for the treatment of a person infected with hiv
BR112012022620A2 (pt) "equipamento para tratamento de recipientes de produto quimíco"
HRP20151393T8 (hr) UPORABA BENZIDAMINA U LIJEČENJU BOLESTI KOJE SU p40-OVISNE
ZA201405910B (en) Use of modafinil in the treatment of cocaine addicts
PT2637974T (pt) Composição multifuncional para o tratamento de desinfecção da água e utilização desta composição
BR112012025829A2 (pt) ''composição de tratamento, composição líquido e utilização''
AP3019A (en) Use of ferroquine in the treatment or prevention of malaria
ES1073878Y (es) "cuadro de pintura o similar"

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: SALIX PHARMACEUTICALS, LTD. (US) , NAPO PHARMACEUT

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: NAPO PHARMACEUTICALS, INC. (US) , SALIX PHARMACEUTICALS, INC. (US)

Owner name: NAPO PHARMACEUTICALS, INC. (US) , SALIX PHARMACEUT

B25A Requested transfer of rights approved

Owner name: NAPO PHARMACEUTICALS, INC. (US)

B25G Requested change of headquarter approved

Owner name: NAPO PHARMACEUTICALS, INC. (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]